EMA valida dos solicitudes de Daiichi Sankyo para terapias triples contra el colesterol
- La EMA validó dos solicitudes de autorización de Daiichi Sankyo para terapias contra el colesterol con tres fármacos en una sola pastilla.
- De autorizarse, serían las primeras combinaciones triples orales en una sola pastilla para reducir el colesterol en la Unión Europea.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610290727BIZWIRE_USPR_____20261029_BW012837) on October 29, 2026, and is solely responsible for the information contained therein.